Biogen bids farewell to Aduhelm after tumultuous journey in Alzheimer’s
The shelving of Biogen’s troubled Alzheimer’s drug caps a turbulent journey, with Leqembi now receiving the company’s full attention.
The shelving of Biogen’s troubled Alzheimer’s drug caps a turbulent journey, with Leqembi now receiving the company’s full attention.
What's Your Reaction?
